Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.12 USD
Change Today -0.12 / -1.46%
Volume 842.0K
SGYP On Other Exchanges
Symbol
Exchange
NASDAQ GS
NASDAQ CM
Frankfurt
As of 1:00 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

synergy pharmaceuticals inc (SGYP) Snapshot

Open
$8.28
Previous Close
$8.24
Day High
$8.42
Day Low
$8.11
52 Week High
07/7/15 - $10.15
52 Week Low
10/10/14 - $2.45
Market Cap
868.6M
Average Volume 10 Days
3.3M
EPS TTM
$-1.12
Shares Outstanding
107.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SYNERGY PHARMACEUTICALS INC (SGYP)

synergy pharmaceuticals inc (SGYP) Related Businessweek News

No Related Businessweek News Found

synergy pharmaceuticals inc (SGYP) Details

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders; and for the treatment of constipation-predominant irritable bowel syndrome GI disorders. The company is also developing SP-333, which is in Phase II clinical trials to treat opioid induced constipation, as well as in Phase Ib clinical trials to treat ulcerative colitis. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.

35 Employees
Last Reported Date: 03/16/15

synergy pharmaceuticals inc (SGYP) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $750.0K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $276.0K
Chief Medical Officer and Executive Director
Total Annual Compensation: $445.3K
Chief Scientific Officer
Total Annual Compensation: $392.0K
Compensation as of Fiscal Year 2014.

synergy pharmaceuticals inc (SGYP) Key Developments

Synergy Pharmaceuticals Inc. Appoints Troy Hamilton as Chief Commercial Officer

Synergy Pharmaceuticals Inc. announced that Troy Hamilton has joined the company as Chief Commercial Officer. Mr. Hamilton will be responsible for Synergy's overall commercial strategy and execution, and will implement marketing, sales, and commercial operations and infrastructure for the U.S. launch of plecanatide. Troy Hamilton has over 19 years of experience in the pharmaceutical industry, with an emphasis on general management, P&L responsibility, commercialization, partnerships, acquisitions, and global product launches in the gastroenterology and primary care markets. Prior to joining Synergy, Mr. Hamilton held multiple commercial leadership roles over a nine year period within Shire Pharmaceuticals GI Business Unit. Most recently, he was Vice President, Product Strategy and Commercial Lead, responsible for the GI motility, hepatology, and pipeline products. In this role he also led the GI business development efforts and was involved in all of their recent GI-related company acquisitions.

Synergy Pharmaceuticals Seeks Acquisitions

Synergy Pharmaceuticals, Inc. (NasdaqGS:SGYP) may use proceeds to repay any debts and/or invest in or acquire complementary businesses, products or technologies, although it does not have any current commitments or agreements with respect to any such investments or acquisitions as of the date of this prospectus.

Synergy Pharmaceuticals, Inc. Appoints Timothy Callahan and Richard Daly as New Independent Directors

Synergy Pharmaceuticals Inc. announced that it has appointed Timothy Callahan and Richard Daly as new independent directors to its board. Both Mr. Callahan and Mr. Daly have direct experience in primary care and gastrointestinal markets and have led large organizational change and successful business growth, in a variety of areas, including all aspects of commercial, acquisitions, partnerships and product launches. Mr. Callahan is a global life sciences business leader with over 21 years of experience in pharmaceutical and biologic commercialization, most recently with the Actavis organization. Mr. Daly has over 20 years of commercial pharmaceutical experience working in positions of progressive responsibility in sales, marketing and operations. Recently, Mr. Daly was the President of U.S. Diabetes for the joint alliance between Bristol-Myers Squibb and AstraZeneca.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGYP:US $8.12 USD -0.12

SGYP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan plc $336.86 USD -2.64
Almirall SA €17.75 EUR -1.22
Ironwood Pharmaceuticals Inc $10.29 USD -0.24
Shire PLC 5,700 GBp +95.00
Sucampo Pharmaceuticals Inc $21.69 USD -1.02
View Industry Companies
 

Industry Analysis

SGYP

Industry Average

Valuation SGYP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SYNERGY PHARMACEUTICALS INC, please visit www.synergypharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.